Evidence map›Paper›PMID 28249786›Full record

ArticleNeuroscience letters2017

Adrenocorticotropic hormone protects learning and memory function in epileptic Kcna1-null mice.

Morris H Scantlebury, Kyoung-Chul Chun, Shun-Chieh Ma, Jong M Rho, Do Young Kim

Open access · greenAbstract read
In one paragraph

Article in Neuroscience letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Hypothalamic-Pituitary-Adrenal Axis and Epilepsy.Journal of clinical neurology (Seoul, Korea) · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 3 countries.

Morris H ScantleburyDepartment of Pediatrics, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Kyoung-Chul ChunDepartment of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph Hospital and Medical Center Phoenix, Arizona, USA; Department of Obstetrics and Gynecology, College of Medicine, Inje University, Ilsan-Paik Hospital, Gyeonggi, Republic of Korea.
Shun-Chieh MaDepartment of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph Hospital and Medical Center Phoenix, Arizona, USA.
Jong M RhoDepartment of Pediatrics, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Clinical Neurosciences, Physiology and Pharmacology, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada.
Do Young KimDepartment of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph Hospital and Medical Center Phoenix, Arizona, USA. Electronic address: doyoung.kim@dignityhealth.org.
Alberta Children's Hospital · CABarrow Neurological Institute · USInje University Ilsan Paik Hospital · KRSt. Joseph Hospital · USUniversity of Calgary · CA

Funding

Metabolic Mechanisms of Functional Neuroprotection in Epileptic BrainR01NS070261 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI KIM, DO YOUNG · 2010 to 2014
$1.6M
NINDS NIH HHS R01 NS070261
6 · The paper itself

Abstract

ACTH, a member of the melanocortin family of peptides, is often used in the treatment of the developmental epileptic encephalopathy spectrum disorders including, Ohtahara, West, Lennox Gastaut and Landau-Kleffner Syndromes and electrical status epilepticus of sleep. In these disorders, although ACTH is often successful in controlling the seizures and/or inter-ictal EEG abnormalities, it is unknown whether ACTH possesses other beneficial effects independent of seizure control. We tested whether ACTH can ameliorate the intrinsic impairment of hippocampal-based learning and memory in epileptic Kcna1-null (KO) mice. We found that ACTH - administered in the form of Acthar Gel given i.p. four times daily at a dose of 4 IU/kg (16 IU/kg/day) for 7days - prevented impairment of long-term potentiation (LTP) evoked with high-frequency stimulation in CA1 hippocampus and also restored spatial learning and memory on the Barnes maze test. However, with this treatment regimen, ACTH did not exert a significant effect on the frequency of spontaneous recurrent seizures. Together, our findings indicate that ACTH can ameliorate memory impairment in epileptic Kcna1-null mice separate from seizure control, and suggest that this widely used peptide may exert direct nootropic effects in the epileptic brain.

Indexed as

Adrenocorticotropic HormoneAnimalsElectroencephalographyEpilepsyEpilepsy, Temporal LobeExcitatory Postsynaptic PotentialsKv1.1 Potassium ChannelLearningMaze LearningMemoryMice, KnockoutNeuroprotective AgentsAdrenocorticotropic HormoneKcna1 protein, mouseKv1.1 Potassium ChannelNeuroprotective AgentsACTHEpilepsyHippocampusKcna1-null miceMemory consolidationNootropic effect

Identifiers

PMID28249786
PMCPMC5774237
OpenAlexW2592092518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.